3 articles
Sanofi raised its annual sales growth forecast to a low-teens percentage, driven by strong demand for Dupixent. The company also announced plans for potential M&A deals exceeding €5 billion to secure
Sanofi will pay Regeneron $1 billion upfront plus up to $7 billion in milestones to expand their immunology antibody partnership, including Dupixent. The deal settles litigation, splitting costs and p
Sanofi exceeded first-quarter earnings expectations with a 30.8% surge in Dupixent sales, while preparing for CEO Belén Garijo to take over in April after Paul Hudson's departure.
ChemBrief